{"url_path":"/sec/adgm/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 ****Exhibits","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-082769-index.html","accession_number":"0001104659-26-082769","cik":"0002006986","ticker":"ADGM","issuer_name":"Adagio Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-082769-index.html","primary_entity_key":"0002006986","primary_entity_name":"Adagio Medical Holdings, Inc."},"word_count":1309,"has_tables":true,"body_markdown":"**Item 15.****Exhibits\nand Financial Statement Schedules.**\n\n \n\n(b) Exhibits.\n\n \n\nThe following exhibits are filed as part of,\nor incorporated by reference into, this Amendment.\n\n \n\n**No.**\n \n**Description\nof Exhibit**\n\n[2.1](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-1.htm)\n \n[Business Combination Agreement,\ndated as of February 13, 2024, by and among Aja HoldCo, Inc., ARYA Sciences Acquisition Corp IV, Aja Merger Sub 1, Aja\nMerger Sub 2, Inc. and Adagio Medical, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current\nReport on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-1.htm)\n\n[2.2](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-2.htm)\n \n[Consent and Amendment No. 1\nto the Business Combination Agreement, dated as of June 25, 2024, by and among ARYA Sciences Acquisition Corp IV and Adagio\nMedical, Inc. (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed with\nthe SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-2.htm)\n\n[3.1](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-1.htm)\n \n[Amended and Restated Certificate\nof Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K\nfiled with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-1.htm)\n\n[3.2](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-2.htm)\n \n[Amended and Restated By-Laws\nof the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the\nSEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-2.htm)\n\n[4.1](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-1.htm)\n \n[Form of Base Warrant\nAgreement (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC\non August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-1.htm)\n\n[4.2](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-2.htm)\n \n[Form of Pre-Funded\nWarrant Agreement (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with\nthe SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-2.htm)\n\n[4.3](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-12.htm)\n \n[Form of Convertible\nNote (incorporated by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K filed with the SEC on\nAugust 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-12.htm)\n\n[4.4](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-3.htm)\n \n[Form of Convert Warrant\nAgreement (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC\non August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-3.htm)\n\n[4.5](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-4.htm)\n \n[Specimen Common Stock Certificate\nof New Adagio (incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed with the\nSEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex4-4.htm)\n\n[4.6](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex4-1.htm)\n \n[Form of Pre-Funded\nWarrant Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with\nthe SEC on October 15, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex4-1.htm)\n\n[4.7](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex4-2.htm)\n \n[Form of Milestone\nWarrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC\non October 15, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex4-2.htm)\n\n[10.1](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-1.htm)\n \n[Form of Convertible\nSecurity Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K\nfiled with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-1.htm)\n\n[10.2](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-2.htm)\n \n[Investor Rights Agreement,\ndated as of February 13, 2024, by and among ARYA, ListCo, the Perceptive PIPE Investor, the Sponsor and the other parties thereto\n(incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on August 6,\n2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-2.htm)\n\n[10.3](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-3.htm)\n \n[Sponsor Letter Agreement,\ndated February 13, 2024, by and between ARYA Sciences Acquisition Corp, ARYA Sciences Holdings IV, Todd Wider, Michael Henderson,\nLeslie Trigg, Joseph Edelman, Adam Stone, Michael Altman, Konstantin Poukalov and Adagio Medical, Inc. (incorporated by reference\nto Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-3.htm)\n\n[10.4+](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-5.htm)\n \n[Form of New Adagio\n2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K\nfiled with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-5.htm)\n\n[10.5+](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-6.htm)\n \n[Form of New Adagio\n2024 Key Employee Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on\nForm 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-6.htm)\n\n[10.6+](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-7.htm)\n \n[Form of New Adagio\n2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K\nfiled with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-7.htm)\n\n[10.7](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-8.htm)\n \n[Form of New Adagio\nIndemnity Agreement (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed\nwith the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-8.htm)\n\n[10.8](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-9.htm)\n \n[Convert Guaranty, dated\nas of July 31, 2024, by and among Adagio and the other parties thereto (incorporated by reference to Exhibit 10.9 to the\nCompany’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-9.htm)\n\n[10.9](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-10.htm)\n \n[Convert Security Document,\ndated as of July 31, 2024, by and among New Adagio, Adagio and the other parties thereto (incorporated by reference to Exhibit 10.10\nto the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-10.htm)\n\n \n\n \n\n \n\n \n\n[10.10](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-11.htm)\n \n[Registration\nRights Agreement dated as of July 31, 2024, by and among New Adagio, Perceptive Life Sciences Master Fund, Ltd. and the\nother parties thereto (incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K filed\nwith the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex10-11.htm)\n\n[10.11](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex10-2.htm)\n \n[Form of Registration\nRights Agreement, dated October 14, 2025, by and among the Company and each of the several purchasers signatory thereto (incorporated\nby reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000110465925099535/tm2528783d1_ex10-2.htm)\n\n[10.12+](https://www.sec.gov/Archives/edgar/data/2006986/000155837024016265/adgm-20241211xex10d2.htm)\n \n[Offer Letter, dated December 12,\n2024, by and between the Company and Todd Usen (incorporated by reference to Exhibit 10.2 to the Company’s Current Report\non Form 8-K filed with the SEC on December 16, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000155837024016265/adgm-20241211xex10d2.htm)\n\n[10.13+](https://www.sec.gov/Archives/edgar/data/2006986/000110465925110345/adgm-20250930xex10d1.htm)\n \n[Amended and Restated Offer\nLetter, dated September 3, 2025, between the Company and Deborah Kaster (incorporated by reference to Exhibit 10.1 to the\nCompany’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000110465925110345/adgm-20250930xex10d1.htm)\n\n[10.14](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex10d24.htm)\n \n[Tenth Amendment to the\nFacilities and Services Agreement, dated August 1, 2024, between Fjord Ventures, LLC and Legacy Adagio (incorporated by reference\nto Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex10d24.htm)\n\n[19.1](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex19d1.htm)\n \n[Insider Trading Policy\n(incorporated by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 27,\n2025).](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex19d1.htm)\n\n[24.1](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231x10k.htm#SIGNATURES)\n \n[Power of Attorney (included\non signature page) (incorporated by reference to Exhibit 24.1 to the Company’s Annual\nReport on Form 10-K filed with the SEC on March 27, 2026)](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231x10k.htm#SIGNATURES)\n\n[31.1*](tm2620259d1_ex31-1.htm)\n \n[Certification of Principal\nExecutive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted Pursuant to Section 302\nof the Sarbanes-Oxley Act of 2002.](tm2620259d1_ex31-1.htm)\n\n[31.2*](tm2620259d1_ex31-2.htm)\n \n[Certification of Principal\nFinancial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted Pursuant to Section 302\nof the Sarbanes-Oxley Act of 2002.](tm2620259d1_ex31-2.htm)\n\n[32.1](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231xex32d1.htm)\n \n[Certification of Principal\nExecutive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n(incorporated by reference to Exhibit 32.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 27,\n2026).](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231xex32d1.htm)\n\n[32.2](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231xex32d2.htm)\n \n[Certification of Principal\nFinancial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n(incorporated by reference to Exhibit 32.2 to the Company’s Annual Report on Form 10-K filed with the SEC on March 27,\n2026).](https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/adgm-20251231xex32d2.htm)\n\n[97.1](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex97d1.htm)\n \n[Policy Relating to Recovery\nof Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K\nfiled with the SEC on March 27, 2025).](https://www.sec.gov/Archives/edgar/data/2006986/000155837025003849/adgm-20241231xex97d1.htm)\n\n101.INS*\n \nInline XBRL Instance Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension\nCalculation Linkbase Document\n\n101.SCH*\n \nInline XBRL Taxonomy Extension\nSchema Document\n\n101.DEF*\n \nInline XBRL Taxonomy Extension\nDefinition Linkbase Document\n\n101.LAB*\n \nInline XBRL Taxonomy Extension\nLabels Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension\nPresentation Linkbase Document\n\n104*\n \nInline XBRL for the cover\npage of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.\n\n \n\n \n\n*Filed\nherewith\n\n**Furnished\nherewith\n\n+Indicates management\ncontract or compensatory plan\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned, thereunto duly authorized.\n\n \n\n \n**ADAGIO MEDICAL\nHOLDINGS, INC****.**\n\n \n \n \n\nDate: July 13,\n2026\nBy:\n/s/\nTodd Usen\n\n \n \n\nTodd Usen\n\nChief Executive Officer"}